{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:06:02Z","timestamp":1765422362394,"version":"3.41.2"},"reference-count":9,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dan Med J"],"abstract":"<jats:p>INTRODUCTION. Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.\n\nMETHODS. A total of 97 consecutive patients had a PleurX catheter implanted from 2015 to 2021. We retrieved retrospective data on patients and procedures using the patient's medical records.\n\nRESULTS. A total of 96 (99%) of implantations were successful, and all patients had symptom relief. Six patients (6%) experienced minor or moderate adverse events: three due to infection, two due to leakage and one because of hypotension. The mean residual lifetime was 77 days.\n\nCONCLUSIONS. We established that implantation of the permanent peritoneal PleurX catheter is a safe and efficient treatment of RMA. We emphasise the importance of early detection and intervention in the management of RMA by implantation of a permanent peritoneal catheter.\n\nFUNDING. None.\n\nTRIAL REGISTRATION. Not relevant.<\/jats:p>","DOI":"10.61409\/a02240098","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:31:36Z","timestamp":1736749896000},"page":"1-6","source":"Crossref","is-referenced-by-count":1,"title":["Establishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites"],"prefix":"10.61409","author":[{"given":"Marie Riis","family":"Mortensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tue Duy","family":"Ngyuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Henrik","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Fleming ND, Alvarez-Secord A, Von Gruenigen V et al. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage. 2009;38(3):341-9. https:\/\/doi.org\/10.1016\/j.jpainsymman.2008.09.008","DOI":"10.1016\/j.jpainsymman.2008.09.008"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Meier M, Mortensen FV, Madsen HHT. Malignant ascites in patients with terminal cancer is effectively treated with permanent peritoneal catheter. Acta Radiol Open. 2015;4(7):2058460115579934. https:\/\/doi.org\/10.1177\/2058460115579934","DOI":"10.1177\/2058460115579934"},{"key":"ref2","unstructured":"Department of Health and Human Services, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.0. National Cancer Institute, 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (Sep 2024)"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Richard HM, Coldwell DM, Boyd-Kranis RL et al. Pleurx tunneled catheter in the management of malignant ascites. J Vasc Interv Radiol. 2001;12(3):373-5. https:\/\/doi.org\/10.1016\/s1051-0443(07)61919-8","DOI":"10.1016\/S1051-0443(07)61919-8"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Tapping CR, Ling L, Razack A. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. Br J Radiol. 2012;85(1013):623-8. https:\/\/doi.org\/10.1259\/bjr\/24538524","DOI":"10.1259\/bjr\/24538524"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Narayanan G, Pezeshkmehr A, Venkat S et al. Safety and efficacy of the PleurX catheter for the treatment of malignant ascites. J Palliat Med. 2014;17(8):906-12. https:\/\/doi.org\/10.1089\/jpm.2013.0427","DOI":"10.1089\/jpm.2013.0427"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017;9:115-30. https:\/\/doi.org\/10.2147\/CMAR.S100210","DOI":"10.2147\/CMAR.S100210"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Macken L, Hashim A, Mason L, Verma S. Permanent indwelling peritoneal catheters for palliation of refractory ascites in end-stage liver disease: a systematic review. Liver Int. 2019;39(9):1594-607. https:\/\/doi.org\/10.1111\/liv.14162","DOI":"10.1111\/liv.14162"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Kaya A, Nas OF, Erdogan C. Tunneled peritoneal catheter placement in palliation of malignant ascites: a study with two different types of catheters. Biomed Res Int. 2019;2019:4132396. https:\/\/doi.org\/10.1155\/2019\/4132396","DOI":"10.1155\/2019\/4132396"}],"container-title":["Danish Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T08:35:54Z","timestamp":1753691754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/dmj\/A02240098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":9,"URL":"https:\/\/doi.org\/10.61409\/a02240098","relation":{},"ISSN":["2245-1919"],"issn-type":[{"type":"electronic","value":"2245-1919"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}